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Epstein–Barr virus infection in vitro immortalizes primary B cells.
EBNA2 is an Epstein–Barr virus-encoded transcriptional transacti-
vator that mimics the effects of activated Notch signaling and is
essential for this proliferative response. An assay using Sindbis
virus (SV) as a cell death inducer revealed that, like Notch, EBNA2
also has antiapoptotic activity. We show that Nur77 is a mediator
of SV-induced cell death and that EBNA2 antiapoptotic activity
results from interaction with Nur77. EBNA2 colocalized with Nur77
in transfected cells and coprecipitated with Nur77 in IB4 B cells.
EBNA2 binds to Nur77 through sequences in the EBNA2 amino acid
123–147 conserved domain and an EBNA2 mutant unable to bind
Nur77 also lost the ability to protect cells from SV-induced apo-
ptosis. EBNA2 exerted its antideath function by retaining Nur77 in
the nucleus and preventing Nur77 from targeting mitochondria in
response to apoptotic stimuli. Thus, targeting of Nur77 can be
added to the list of strategies used by viruses to counter apoptosis.
Epstein–Barr virus (EBV) is associated with a variety ofhuman malignancies (1). The nuclear latency gene products
EBNA1, EBNA2, EBNA3A, and EBNA3C, and the membrane
protein LMP-1 are essential for in vitro immortalization of B cells
(2). Other latency proteins, EBNA-LP, LMP2A, and the proteins
encoded by the BamHI-A rightward transcripts (BARTs) either
contribute to immortalization efficiency or are likely to be
important for the establishment and maintenance of life-long
in vivo latency, which is itself a factor in the development of
EBV-associated disease (3–10).
EBNA2 functions as a transcriptional transactivator to regu-
late the pattern of EBV latency gene expression in B cells and
to modify cellular gene expression with a resultant stimulation of
G0 to G1 cell cycle progression (11, 12). In its transcriptional role,
EBNA2 mimics the effects of activated Notch (13, 14). Notch is
an evolutionarily conserved, surface receptor that mediates
cell–cell signaling to influence developmental and cell fate
decisions (15, 16). Ligand binding induces proteolytic cleavage
events that release the intracellular domain of Notch, NotchIC,
which translocates to the nucleus where it functions as a tran-
scriptional activator (17). EBNA2 and NotchIC both target
responsive promoters through the cellular DNA binding protein
CBF1RBP-Jk (18). CBF1 acts as a transcriptional repressor by
bringing to the promoter a histone deacetylase-containing com-
plex (19–23) that deacetylates histones, favors nucleosome for-
mation, and generates a chromatin state that is unfavorable for
transcription (24). Constitutive repression occurs in part because
nuclear import of CBF1 depends on preassociation with mem-
bers of the corepressor complex (25). EBNA2 and NotchIC
activate CBF1 bound promoters by competing away the core-
pressor complex (26, 27). Interactions with coactivator proteins
such as pCAF, CBP, and p300 (28–30), and with the SWISNF
complex (31) facilitate the conversion to transcriptional activa-
tion. The common mechanism of transcriptional regulation by
EBNA2 and NotchIC is reflected in functional assays. EBNA2
and activated Notch can partially substitute for each other in B
cell proliferation and muscle differentiation assays (32–34).
A yeast two-hybrid assay revealed that NotchIC interacts with
Nur77 (35). Nur77 (TR3, NGFI-B) is an orphan member of the
nuclear hormone receptor superfamily. Nur77 was originally
identified as an immediate-early gene that was rapidly induced
in fibroblasts by serum stimulation and in PC12 cells by nerve
growth factor (36). Nur77 is a transcription factor that binds to
NBRE motifs as a monomer and to palindromic NurRE sites as
a dimer (37). Nur77 also heterodimerizes with the retinoid-X
receptor (RXR) to down-regulate RXR activity (38). Nur77 has
a second function as a mediator of apoptosis. In response to an
apoptotic stimulus, the normally nuclear Nur77 translocates to
the cytoplasm where it targets mitochondria to induce cyto-
chrome c release (39). NotchIC was found to inhibit Nur77-
mediated apoptosis in T cells (35).
Viral infection is an effective trigger of cellular apoptosis and
viruses have evolved a variety of mechanisms to counter the
apoptotic response (40). EBV has been thought to counter
apoptosis during latency indirectly through LMP1-mediated
activation of NF-B-regulated genes (41, 42). The Bcl-2 ho-
mologs encoded by the EBV BHRF1 and BALF1 ORFs are
expressed only during the viral lytic cycle, presumably to prevent
premature cell death during active EBV replication (43–45). We
now show that EBNA2 mimicry of Notch activity includes the
ability to protect against apoptosis.
Sindbis virus (SV) infection has been used as an apoptotic
stimulus to examine the protective effects of Bcl-2 family mem-
bers and their viral homologs (46). We found that Nur77 is also
a mediator of SV-induced apoptosis and that EBNA2 blocks this
apoptotic response through interaction with Nur77.
A tumorigenic cell phenotype is associated not only with
increased proliferation but also with an increased resistance to
apoptosis. Our experiments suggest that in certain disease
settings, expression of EBNA2 could be providing such a cell
survival advantage by blocking the effects of stimuli that elicit
Nur77-mediated cell death.
Materials and Methods
Plasmids and Viruses. The plasmids pSG5-EBNA2 (pPDL151),
Flag-NotchIC (pJH279), and pEFBOS-GST-Nur77 have been
described (13, 35, 47). pSG5-EBNA2 with amino acids 123–147
deleted (pPDL328) was obtained from P. Ling (Baylor College
of Medicine, Waco). Bacterial GST-EBNA2 fusion proteins
were made in pGEX2T (Pharmacia; ref. 47). Nur77 was cloned
into the BglII site of a modified pSG5 vector to generate
HA-Nur77, into a lentivirus vector (48) to generate lenti-Nur77,
and into pEGFP-C1 (CLONTECH) to generate pEGFP-Nur77.
SV vectors expressing EBNA2 (SV-E2), reverse EBNA2 (SV-
revE2), mutant EBNA2 (SV-E2123–147), Nur77 (SV-N77),
and antisense Nur77 (SV-asN77) were generated by blunt end
ligation into the BstEII site of the SV vector dsTE12Q (49, 50).
Virus stocks were generated and titered using BHK-21 cells as
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described (46). SV-BCL-xL was provided by J. M. Hardwick
(Johns Hopkins University).
Cell Death. BHK-21 or NIH 3T3 cells were infected with SV at a
multiplicity of infection (moi) of 5 plaque-forming units per cell.
Infections were performed in triplicate. Cell viability was deter-
mined by trypan blue exclusion as described (45), or using the
lactate dehydrogenase (LDH) assay kit (Promega). The intra-
cellular cleavage of poly (ADP-ribose) polymerase (PARP) was
determined at 48 hr after infection by using whole cell extracts
from SV-infected cells. Western blots were probed with anti-
PARP antibody (C-2–10, CLONTECH).
Immunofluorescence Assays. NIH 3T3 cells were seeded on cham-
ber slides (LabTek) at 0.8  105 cells per well and transfected
with GFP-Nur77 (0.4 g) by using Lipofectamine Plus (GIBCO
BRL). Cells were infected with SV 12 hr after transfection. After
24 hr, cells were washed and fixed in 2% paraformaldehyde in
PBS for 5 min at room temperature. Fixed cells were washed and
permeabilized in 0.2% Triton X-100 in PBS for 20 min on ice.
For EBNA2 staining, cells were incubated with anti-EBNA2
antibody (PE2; Dako), followed by donkey anti-mouse IgG
conjugated with rhodamine (Jackson ImmunoResearch). For
mitochondrial staining, MitoTracker-Red (Molecular Probes;
200 nM) was added to the medium 30 min before fixation. Slides
were mounted with Vectashield containing DAPI (Vector Lab-
oratories), and images were captured using a fluorescence
microscope and IMAGE PRO software (Media Cybernetic, Silver
Spring, MD) or a confocal microscope with COMPIX software.
GST Affinity Assays. Generation of transfected cell extracts, GST
binding, and Western blot analyses were carried out as described
(27). Nur77 was detected using anti-Nur77 monoclonal antibody
(51), or anti-HA antibody (Upstate Biotechnology, Lake Placid,
NY). For mammalian GST affinity assays, 293T cells (2  107)
were transfected with 15 g of each plasmid by using calcium
phosphate precipitation. Cells were collected 2 days after trans-
fection and homogenized in NETN buffer [20 mM TrisHCl (pH
8.0)100 mM NaCl0.5% Nonidet P-401 mM EDTA] contain-
ing protease inhibitor (0.2 g/ml aprotinin0.2 mM PMSF).
Lysates were incubated with glutathione-sepharose 4B beads for
4 hr at 4°C. After binding, the beads were pelleted and washed
six times with NETN buffer, resuspended in 35 l of SDS sample
buffer, and boiled for 5 min. Samples were analyzed by SDS
PAGE and Western blotting with anti-EBNA2 antibody, and
then reprobed with anti-GST antibody (B-14; Santa Cruz
Biotechnology).
Immunoprecipitation. EBV-infected IB4 and P3HR-1 B cells
(4.0 107) or IB4 cells infected with lenti-Nur77 (2 107) were
harvested and lysed with RIPA buffer [1.0% Nonidet P-40150
mM NaCl50 mM TrisHCl (pH 7.4)1 mM DTT1 mM NaF1
mM Na3VO410 g/ml leupeptin2 g/ml aprotinin1 mM
PMSF] at 4°C. Cell extracts were precleared on protein G-
sepharose 4 Fast Flow (Amersham Pharmacia Biosciences).
Cleared extracts were incubated with anti-EBNA2 or -Nur77
antibodies and protein G sepharose beads at 4°C. Beads were
washed six times with RIPA buffer, eluted in gel loading buffer,
and separated by SDSPAGE.
Results
EBNA2 Protects Against SV-Induced Apoptosis. To evaluate whether
EBNA2 possessed any antiapoptotic function, recombinant SV
were generated that contained the EBNA2 ORF inserted in
either sense or antisense orientation into a unique cloning site
behind a duplicated copy of the SV subgenomic promoter (Fig.
1A). It has previously been demonstrated that SV infection
induces programmed cell death and that expression of the
antiapoptotic BCL-xL protein by recombinant SV is protective
(50). NIH 3T3 cells were infected with SV-wt and SV-BCL-xL,
as well as the sense and reverse EBNA2 SV at a moi of 5 and cell
viability was followed over time by using trypan blue exclusion
(Fig. 1B). The SV-wt and reverse EBNA2 SV each induced cell
death in the bulk (70–90%) of the cell population by 54 hr
postinfection while expression of BCL-xL was completely pro-
tective. Expression of EBNA2 from SV-E2 also resulted in
complete protection at 48 hr postinfection and substantial
protection at 54 hr. Apoptosis is associated with intracellular
cleavage of specific protein substrates such as PARP, which is
cleaved to 85- and 30-kDa fragments. Analysis of PARP in
SV-infected cells showed that cleaved PARP was detected as
expected in SV-wt infected cells (52), but not in SV-E2- or
SV-BCL-xL-infected cells (Fig. 1C). This indicates that SV-
induced apoptosis of NIH 3T3 cells was inhibited by EBNA2.
Nur77 Is a Key Mediator of SV-Induced Apoptosis. The pathways
leading to SV-induced apoptosis are incompletely understood,
although accumulation of ceramide and induction of caspases
are known to be factors (52–54). We investigated whether Nur77
might play a role in SV-induced apoptosis. Recombinant SV
carrying sense and antisense versions of the Nur77 ORF were
generated and titered. NIH 3T3 cells were mock infected or
infected with SV-wt or SV-asN77. Four hours postinfection, cells
were harvested and Nur77 expression was analyzed by immu-
noprecipitation with anti-Nur77 antibody followed by Western
blotting (Fig. 2A). Infection with SV-wt induced Nur77 expres-
sion and this was effectively blocked by antisense Nur77. To
assess the role of Nur77 induction in SV-induced cell death, NIH
3T3 cells were mock infected or infected with SV-wt, SV-BCL-
xL, SV-N77, or SV-asN77 at a moi of 5 and cell death was
Fig. 1. Inhibition of SV-induced cell death by EBNA2. (A) Diagram of the SV
vector. SP6, heterologous SP6 promoter; NS, nonstructural genes; S, structural
genes. (B) NIH 3T3 cells were mock infected or infected at a moi5 with SV-wt,
SV-BCL-xL, SV-EBNA2 (E2), or SV-revEBNA2 (revE2). Cell viability was deter-
mined by trypan blue exclusion. The data shown are the mean of three assays
with the standard deviation provided. (C) NIH 3T3 cells were infected with
virus at a moi 5, and harvested at 48 hr after infection. Intact PARP and the
85-kDa cleaved product (arrowed) were detected by Western blotting. The
same blot was stripped and reprobed with anti-EBNA2 antibody (Lower).











assessed at 48 hr postinfection by using a LDH release assay. Cell
death was induced efficiently by the SV-wt and SV-N77 viruses
(Fig. 2B). However, expression of antisense Nur77 was equally
as effective as BCL-xL at protecting against SV-induced
apoptosis.
Nur77 functions in the nucleus as a transcription factor, but in
the presence of certain apoptotic stimuli Nur77 translocates to
the cytoplasm where it targets mitochondria (39). To demon-
strate that the behavior of Nur77 was consistent with a role in
SV-induced apoptosis, NIH 3T3 cells were transfected with a
GFP-Nur77 fusion protein and 12 hr later the cells were either
mock infected or infected with SV-wt, and the intracellular
localization of GFP-Nur77 was visualized. In mock-infected cells
(Fig. 2C Upper), GFP-Nur77 (green) was present in the nucleus
and the GFP signal was physically distinct from the cytoplasmic
mitochondrial staining detected using MitoTracker-Red dye
(red). After SV infection (Fig. 2C Lower), the GFP-Nur77 was
detected in the cytoplasm where it colocalized with the Mito-
Tracker-Red mitochondrial staining in merged images.
EBNA2 Interacts with Nur77. Because Nur77 is involved in SV-
induced apoptosis and EBNA2 is protective in SV infected cells,
we sought to determine whether there was any interaction
between EBNA2 and Nur77. Firstly, HeLa cells were cotrans-
fected with GFP-Nur77 and EBNA2 expression vectors and the
transfected cells were monitored for GFP-fluorescence and
EBNA2 by using anti-EBNA2 monoclonal antibody and a
rhodamine-conjugated secondary antibody. EBNA2 and Nur77
were observed to colocalize with a pattern of nuclear punctate
staining in the transfected cells (Fig. 3).
To determine whether EBNA2 and Nur77 interacted in EBV
infected B cells, an immunoprecipitation was performed on
extracts of IB4 cells that are latently EBV infected and express
EBNA2. Extracts from P3HR-1 cells were used as a control.
P3HR1 EBV carries an EBNA2 deletion. Endogenous EBNA2
was immunoprecipitated with anti-EBNA2 antibody and West-
ern blots of the immunoprecipitated proteins were incubated
with anti-Nur77 antibody. Nur77 coprecipitated with EBNA2
from IB4 cells (Fig. 4A Upper). Nur77 was not detected in the
control mouse IgG precipitates, nor in the immunoprecipitate
from P3HR-1 cells. The presence of EBNA2 in the IB4 immu-
noprecipitate was confirmed by stripping the blot and reprobing
with anti-EBNA2 antibody (Fig. 4A Lower). Using lenti-Nur77-
infected IB4 cells, we also demonstrated coprecipitation of
EBNA2 and Nur77 in cell extracts immunoprecipitated with
anti-Nur77 antibody (Fig. 4B Upper).
To further pursue the question of interaction between these
two proteins, a GST-affinity assay was performed using GST-
fusion proteins expressing different segments of EBNA2 (Fig.
5A) and extract from 293T cells transfected with HA-Nur77.
Immunoblot analysis of the GST-bound proteins revealed that
there was no interaction between Nur77 and GST alone (Fig. 5B,
lane 2) or between Nur77 and GST fusions carrying the EBNA2
C terminus (amino acid 367–425, lane 4; amino acid 252–425,
lane 6) or N terminus (amino acid 1–58, lane 7). However, Nur77
bound to GST fusion proteins carrying an internal region of
EBNA2 (amino acid 101–154, lane 3; amino acid 128–252, lane
5). Interestingly, the Nur77 protein detected in lanes 3 and 5
migrated at the same position as a minor Nur77 species in the
transfected cell extract and slightly more slowly than the major
Nur77 band. The Nur77 species interacting with endogenous
EBNA2 in IB4 cells (Fig. 4A) also migrated in the position of the
modified Nur77 protein. This raises the possibility that a mod-
ified form of Nur77 might preferentially interact with EBNA2.
Phosphorylation is known to modulate both the function and
intracellular localization of Nur77 (38, 55).
EBNA2 Amino Acid 123–147 Are Necessary for Nur77 Interaction and
for Inhibition of Apoptosis. The two GST-EBNA2 fusion proteins
that showed interaction with Nur77 overlapped between amino
Fig. 2. Nur77 is a mediator of SV-induced apoptosis. (A) NIH 3T3 cells (2 
107) were infected with either SV-wt or SV-antisenseNur77 (asN77) for 4 hr.
Cell lysates were immunoprecipitated with anti-Nur77 antibody and the
immunoprecipitates were analyzed by immunoblotting with anti-Nur77 an-
tibody. (B) NIH 3T3 cells were mock infected or infected at a moi  5 with
SV-wt, SV-BCL-xL, SV-Nur77 (N77), or SV-antisenseNur77 (asN77). Cell death
was measured 48 hr after infection by using an LDH release assay. The data
shown are the mean of three assays with the standard deviation provided. (C)
NIH 3T3 cells were transfected with GFP-Nur77 and 12 hr later the cells were
either mock infected (Upper) or infected with SV-wt (Lower). After 24 hr, cells
were fixed, and stained with DAPI (nuclei; blue) and MitoTracker-Red (mito-
chondria; red). GFP-Nur77 (green) was nuclear in mock-infected cells (Upper)
but colocalized with mitochondria in SV-infected cells.
Fig. 3. EBNA2 colocalizes with Nur77. IFA performed on HeLa cells cotrans-
fected with GFP-Nur77 (green) and EBNA2 (red) and stained with anti-EBNA2
antibody. In the merged confocal images, EBNA2 and Nur77 colocalized
(yellow).
Fig. 4. Coprecipitation of endogenous EBNA2 and Nur77. (A) Endogenous
EBNA2 protein was immunoprecipitated with anti-EBNA2 antibody (lanes 1
and 3) or with control antibody (lanes 2 and 4) from extracts of IB4 or control
P3HR-1 cells. Western blots of the immunoprecipitates were probed with
anti-Nur77 antibody (BD PharMingen). The blot was reprobed with anti-
EBNA2 antibody to show the presence of EBNA2 (Lower). (B) Extracts from IB4
cells infected with lenti-Nur77 were subjected to immunoprecipitation with
anti-Nur77 antibody and immunoblotting with anti-EBNA2 antibody to con-
firm coprecipitation of EBNA2 and Nur77. The blot was reprobed with anti-
Nur77 antibody to show the presence of Nur77 (Lower).
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acids 128 and 154, suggesting that this region was important for
Nur77 binding. To directly assess the requirement for this
domain, an EBNA2 mutant was tested that was deleted for
amino acids 123–147. A eukaryotic GST-affinity assay was
performed in 293T cells cotransfected with expression plasmids
for GST-Nur77 and either EBNA2wt or EBNA2123–147.
Immunoblot analysis of the GST-bound protein detected
EBNA2-wt bound to GST-Nur77, but no binding of EBNA2
123–147 was observed (Fig. 5C Top). Equal amounts of GST
protein were bound to the glutathione beads, as shown by
reprobing of the immunoblot with anti-GST antibody (Fig. 5C
Middle). The transfected cells expressed comparable amounts of
the EBNA2wt and mutant EBNA2123–147 proteins as as-
sessed by immunoblot analysis using anti-EBNA2 monoclonal
antibody (Fig. 5C Bottom).
To determine the effect of loss of Nur77 binding on the
antiapoptotic function of EBNA2, a recombinant SV was gen-
erated that expressed EBNA2123–147. Cell death was mea-
sured in NIH 3T3 cells infected with SV-E2, SV-revE2, SV-
E2123–147, or control SV recombinants (Fig. 6A). SV-
E2123–147 showed reduced efficacy at protecting against cell
death compared with SV-E2 and was only marginally more
protective than the antisense EBNA2 recombinant SV. Consis-
tent with this observation, PARP cleavage was detected in
SV-E2123–147-infected cells (Fig. 6B). Thus, loss of Nur77
interaction correlated with loss of antiapoptotic function.
EBNA2 and NotchIC Inhibit Nur77 Nuclear Export. Nur77’s proapo-
ptotic activity has recently been linked to the translocation of
Nur77 from the nucleus to the mitochondria (39). We exam-
ined GFP-Nur77 intracellular localization in HeLa cells that
were cotransfected with either EBNA2wt or EBNA2123–147
and then treated with PMA (phorbol 12-myristate 13-acetate)
as an apoptotic stimulus. Cells were then stained for EBNA2
by using anti-EBNA2 antibody and Rhodamine-conjugated
secondary antibody. In cells expressing EBNA2wt, cotrans-
fected GFP-Nur77 was present in the nucleus, whereas in cells
expressing the nonprotective mutant EBNA2123–147 the
GFP-Nur77 had relocalized to the cytoplasm (Fig. 7A). In a
parallel approach, GFP-Nur77-transfected NIH 3T3 cells were
infected with SV expressing either EBNA2wt or EBNA2123–
147. Once again the GFP-Nur77 remained nuclear in the
SV-EBNA2wt-expressing cells and was relocalized to the
cytoplasm in SV-EBNA2123–147-expressing cells (Fig. 7B).
These observations suggest that the antiapoptotic effect of
EBNA2 derives from EBNA2 binding to Nur77 and preventing
mitochondrial targeting by Nur77. NotchIC is known to inhibit
Nur77-mediated apoptosis (35). We wondered whether
NotchIC might behave similarly to EBNA2 and repeated the
assay in HeLa cells, this time cotransfecting Flag-NotchIC and
HA-Nur77. Treatment of the culture with PMA induced
cytoplasmic export of Nur77 in the singly transfected cells, but
in NotchIC-expressing cells Nur77 was retained in the nucleus
(Fig. 7C).
Discussion
Nur77 is a mediator of apoptosis in a variety of cell types. Much
of the work on the apoptotic function of Nur77 and its family
members Nurr1 and Nor1 has focused on T cell receptor
Fig. 5. EBNA2 binds Nur77 through the EBNA2 amino acids 123–147 domain. (A) Schematic of EBNA2 and the GST-EBNA2 proteins. Regions conserved among
primate EBNA2 homologs (74) are shaded. (B) GST-affinity assay in which extract from 293T cells transfected with HA-Nur77 was incubated with purified GST
(lane 2) or with the GST-EBNA2 fusion proteins. Lane 3, E2 (101–154); lane 4, E2 (367–425); lane 5, E2 (128–252); lane 6, E2 (252–425); lane 7, E2 (1–58). Lane 1,
transfected cell extract (10 l). Bound protein was detected by Western blotting using anti-Nur77 antibody. (C) Mammalian GST-affinity assay showing that
deletion of EBNA2 amino acids 123–147 ablates Nur77 binding. (Top) Extracts of 293T cells cotransfected with GST, GST-Nur77, EBNA2wt, or EBNA2123–147
plasmids were incubated with glutathione-Sepharose beads and the bound protein was detected by immunoblotting with anti-EBNA2 antibody. (Middle) The
immunoblot in A was reprobed with anti-GST antibody to demonstrate equal expression of GST and GST-Nur77. (Bottom) Immunoblot of the transfected cell
extracts to show EBNA2 expression.
Fig. 6. Binding to Nur77 is essential for EBNA2 antiapoptotic activity. (A) NIH
3T3 cells were mock infected or infected with the indicated viruses and cell
viability was determined 54 hr postinfection by using the LDH assay. Data
shown are the mean of three assays with the standard deviation provided. The
Nur77 nonbinding EBNA2123–147 was nonprotective. (B) Western blot of
extracts from NIH 3T3 cells infected with the indicated viruses and probed with
anti-PARP antibody to detect PARP cleavage and anti--actin antibody to
show equal loading. The 85-kDa cleaved PARP product is arrowed.











(TCR)-induced apoptosis (56, 57). Nur77 synthesis is induced
during this process and Nur77 is a key mediator (51, 58).
Expression of antisense Nur77 or a dominant-negative Nur77
prevents apoptosis in TCR-stimulated cells, whereas constitutive
expression of Nur77 in thymocytes of transgenic mice leads to
extensive apoptosis (51, 59, 60). Nur77 has also been shown to
be critical for surface IgM-mediated apoptosis of B cell lines
(61–63). In addition, Nur77 participates in the apoptotic re-
sponse induced by agents such as phorbol esters, calcium iono-
phores, and etoposide (39). Viral infection can now be added to
this list. SV infection induced Nur77 expression and abolition of
expression by antisense Nur77 was protective against SV-
induced cell death.
Until recently, it had been assumed that Nur77 apoptotic
function was mediated solely through its gene regulatory activity.
Li et al. (39) demonstrated that appropriate apoptotic stimuli
resulted in relocalization of Nur77 from the nucleus to the
cytoplasm where Nur77 was found to accumulate in the cell
fraction that contained mitochondria. Abrogation of mitochon-
drial targeting by blocking Nur77 nuclear export using leptomy-
cin B treatment or by retargeting the protein to other cell
organelles abolished its apoptotic activity. We showed that
endogenous EBNA2 and Nur77 proteins from latently EBV-
infected IB4 B cells coprecipitated, consistent with a role for
EBNA2 in modifying Nur77 activity. EBNA2 bound Nur77 and
inhibited Nur77 nuclear export induced by either SV or by
treatment with PMA. EBNA2 also countered Nur77-mediated
apoptosis induced by SV infection. Nur77 binding correlated
with EBNA2 antiapoptotic activity in that an EBNA2 mutant
unable to interact with Nur77 was also unable to prevent Nur77
nuclear export and the apoptotic cell response.
Identification of an antiapoptotic function for EBNA2 implies
that EBNA2 contributes to cell survival, as well as to the
proliferative response that occurs on EBV infection. Cell death
can be initiated through multiple second messenger pathways
and Nur77 is involved in only some of these; for example, LNCaP
cells stably expressing antisense Nur77 were not protected from
apoptosis induced by treatment with TNF- (39). The anti-
Nur77 protective effect of EBNA2 may complement the LMP1-
induced survival signals mediated through NF-B up-regulation
of antiapoptotic genes such as A20, Bfl-1, and BCL-2 (42, 64–66)
and provide initial protection before LMP1 expression during
primary EBV infection of B cells. Consistent with such a role,
recombinant EBV deleted for the region of EBNA2 containing
the amino acids 123–147 domain transforms B cells in vitro with
less than 10% of the efficiency of wild-type virus (67, 68). The
majority of EBV-associated tumors do not express EBNA2,
presumably because the EBNA2 and coordinately expressed
EBNA3 latency proteins are highly immunogenic. However,
EBNA2 is expressed in EBV-associated tumors arising in im-
munocompromised patients—for example, in posttransplant
lymphoproliferative disease and in primary central nervous
system lymphomas in AIDS patients (69–71)—and its antiapo-
ptotic activity may be a factor in the development of these
malignancies.
A dual proliferative and antiapoptotic role for EBNA2 mirrors
the activities ascribed to cellular Notch (16, 72). Notch ligands
are expressed on stromal cells and Notch signaling in vitro
induces proliferation of CD34CD38 pluripotent hematopoi-
etic cells (73). Notch is believed to act at multiple stages during
thymocyte development and it has been proposed that the
antiapoptotic effects of Notch influence cell fate decisions by
rescuing cells that would otherwise succumb to cell death by
neglect or by negative selection (56). However, the way in which
NotchIC blocks Nur77 apoptotic function has not been defined.
We found that NotchIC also prevented cytoplasmic transloca-
tion of Nur77 in HeLa cells treated with PMA. Thus, EBNA2
mimicry of NotchIC is extended from their previously recog-
nized shared mechanism of promoter targeting through cellular
CBF1 to a similar mechanism for antiapoptotic activity. This
degree of functional convergence is particularly remarkable in
light of the fact that EBNA2 and Notch do not share obvious
primary sequence homology.
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